PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$28.57 USD
+3.08 (12.08%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $28.58 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
PTCT 28.57 +3.08(12.08%)
Will PTCT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PTCT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PTCT
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PTCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
Here's What Key Metrics Tell Us About PTC Therapeutics (PTCT) Q4 Earnings
Other News for PTCT
PTC Therapeutics just upgraded at Morgan Stanley, here's why
PTC Therapeutics: A Balanced Hold Rating Amid Regulatory Challenges and Upcoming Milestones
RBC Capital Sticks to Their Hold Rating for PTC Therapeutics (PTCT)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Integer Holdings (ITGR), Resmed (RMD) and PTC Therapeutics (PTCT)
PTC Therapeutics price target raised by $1 at Citi, here's why